Long Yu | Biosensor | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Long Yu | Biosensor | Best Researcher Award

Assoc. Prof. Dr. Long Yu | Wuhan University | China

Dr. Long Yu is a highly accomplished Han Chinese researcher, currently serving as a Postdoctoral Fellow in Clinical Medicine at Wuhan University. With a deep passion for pharmaceutical analysis, he has pioneered innovative approaches using lanthanide-based metal-organic frameworks (Ln-MOFs). His academic journey has been marked by excellence, including direct admission to a Ph.D. program and multiple national-level scholarships. Dr. Yu has published over 20 high-impact SCI papers, many in top-tier journals such as Advanced Materials, ACS Nano, and Analytical Chemistry. Recognized for his independent research capabilities, he has secured major national funding, including the NSFC Youth Project and China Postdoctoral Science Foundation grant. His work is shaping the future of biosensing and molecular diagnostics, especially in nucleic acid detection. Dr. Yu’s remarkable academic achievements, innovative research direction, and collaborative impact make him an outstanding candidate for the Best Researcher Award.

Publication Profile: 

Orcid

Education:

Dr. Long Yu’s educational background reflects a consistent trajectory of academic excellence. He completed his Bachelor of Science in Pharmacy at Shihezi University, where he graduated and was directly admitted to a Ph.D. program without an entrance exam. He pursued a Direct-Ph.D. in Pharmacy at Wuhan University, under the mentorship of Prof. Yuxiu Xiao. His doctoral research focused on the rational design and application of programmable lanthanide-based metal-organic frameworks (Ln-MOFs) in pharmaceutical analysis. Currently, he is a Postdoctoral Fellow in Clinical Medicine at Wuhan University, guided by Professors Gaosong Wu and Xiang Zhou. Through his academic journey, Dr. Yu has demonstrated strong interdisciplinary capabilities, combining pharmaceutical sciences, materials chemistry, and biosensing technology to advance the field of molecular diagnostics.

Experience:

Dr. Long Yu has cultivated deep expertise in biosensors and pharmaceutical analysis throughout his academic and research journey. He is currently a Postdoctoral Fellow in Clinical Medicine at Wuhan University, working on translational biosensing technologies with Professors Gaosong Wu and Xiang Zhou. He earned his Ph.D. in Pharmacy at Wuhan University under the supervision of Prof. Yuxiu Xiao, where he led several high-impact research projects on programmable metal-organic frameworks (MOFs). His undergraduate foundation was built at Shihezi University , where he graduated among the top of his class. Dr. Yu has served as the principal investigator for five competitive research grants, including prestigious national funding. His academic footprint includes 21 SCI-indexed publications and significant contributions to both theoretical research and practical biosensor development. He excels at multidisciplinary collaboration, combining chemistry, materials science, and clinical application—demonstrating both leadership and innovation in his research.

Awards and Honors:

Dr. Long Yu has received multiple accolades that highlight his academic and research excellence. During his Ph.D., he was awarded the National Scholarship for Graduate Students twice, a prestigious recognition of outstanding academic performance and research capabilities in China. He also received the 1st Prize for Oral Presentation at the National Academic Symposium for Pharmacy Postgraduates in , and the Excellent Poster Award at the 9th National Conference on Drug Analysis in the same year. In addition to academic awards, he has secured several competitive grants as the Principal Investigator, including the National Natural Science Foundation of China Youth Project, the China Postdoctoral Science Foundation General Program, and the Hubei Province Postdoctoral Innovation Talent Program. These achievements demonstrate both national-level recognition and institutional confidence in his independent research potential, marking him as one of the leading young scientists in his field.

Research Focus:

Dr. Long Yu’s research is centered on the rational design of programmable lanthanide-based metal-organic frameworks (Ln-MOFs) for pharmaceutical analysis and biosensing applications. His work bridges materials science and biomedical engineering, enabling high-performance detection platforms for nucleic acids, neurotransmitters, kinases, and epigenetic modifications. He has developed Ln-MOF-integrated systems with excellent selectivity, sensitivity, and biocompatibility for real-time monitoring and clinical diagnostics. A notable feature of his research is the integration of MOF materials with cutting-edge technologies such as CRISPR-Cas, nanozymes, and multivariate sensing platforms. His innovative designs contribute to amplification-free gene mutation detection, ultra-efficient nucleic acid extraction, and responsive ctDNA biosensors. Dr. Yu’s interdisciplinary approach not only expands the utility of MOFs in biomedicine but also paves the way for smart and customizable sensing systems. With 21 high-quality SCI publications and ongoing funded projects, his work is both academically significant and practically relevant in clinical diagnostics and precision medicine.

Publications Top Notes: 

  1.  Lanthanide MOF-Integrated CRISPR-Cas Technology for Amplification-Free Gene Mutation Assay

  2.  Customized Pyrophosphate Nanosensor Based on Lanthanide MOFs for Nucleic Acids Detection

  3.  Polarity Sensor Using Multivariate Lanthanide MOF for Biosensing Platforms

  4.  Levodopa Cascade Polymerization with MOF Nanozyme for Butyrylcholinesterase Dual-Mode Assay

  5.  Enhancing Kinase Detection via Programmable Lanthanide MOF with ATP-to-ADP Conversion

  6. Ultra-Efficient Nucleic Acids Extraction Using Programmable Lanthanide MOF

  7. Bioreaction-Compatible Bivariate Lanthanide MOF Sensor for ctDNA Detection

  8. Adaptable Cobalt MOF for DNA Epigenetic Modification Detection

  9. Trinity Strategy Using Perovskite Nanozyme for Biomarker Reporting

  10.  Nanoporous Crystalline Materials for Nucleic Acids Recognition

Conclusion:

In conclusion, Dr. Long Yu is highly suitable for the Best Researcher Award based on his exceptional research productivity, innovation in the design and application of Ln-MOFs, and substantial contributions to high-impact journals. His early career achievements, particularly as a postdoctoral fellow, show a promising trajectory that is well-aligned with the criteria of research excellence, originality, and potential societal impact. With continued international exposure, broader interdisciplinary collaboration, and efforts to translate research into clinical or industrial outcomes, Dr. Yu is not only deserving of the current award but is also poised to become a leading figure in his field in the years to come.

Yuxiang Wang | Molecular Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Yuxiang Wang | Molecular Biology | Best Researcher Award

Dr. Yuxiang Wang, Fudan University, China

Dr. Yuxiang Wang is a Principal Investigator and Ph.D. Supervisor at Fudan University, with an extensive background in molecular biology, oncology, and translational medicine. He earned his Ph.D. in Developmental and Molecular Biology from the Albert Einstein College of Medicine, where he worked under the mentorship of Dr. Jeffrey W. Pollard. Following this, he completed a prestigious research fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Wang has built a strong academic and clinical research portfolio, focusing on gliomas and muscular dystrophy. His work utilizes state-of-the-art preclinical models and CRISPR screening technologies to identify novel therapeutic strategies. Dr. Wang is a recipient of numerous honors, including the MSK Society Scholar Award and Shanghai Leading Overseas Talent recognition. He actively collaborates with clinicians to translate lab discoveries into patient therapies, and his prolific publication record reflects deep scientific rigor and innovation.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Research Track Record
    Dr. Wang has published in top-tier journals such as Nature Communications, Science Advances, Cancer Research, and PNAS. His publication record demonstrates consistency, depth, and high impact across multiple domains including glioma biology and gene therapy.

  2. Dual Research Focus
    He leads research in two distinct yet critical biomedical areas—malignant gliomas and muscular dystrophy. This breadth shows versatility and the ability to manage complex translational programs.

  3. Innovative Techniques
    Dr. Wang effectively applies CRISPR-based genetic screening, preclinical mouse models, and patient-derived cell lines—cutting-edge tools that reflect a forward-thinking, high-tech research approach.

  4. International Research Background
    His training and professional experience in both the U.S. (at Memorial Sloan-Kettering Cancer Center) and China make him a bridge between Western and Eastern biomedical research ecosystems.

  5. Leadership and Mentorship
    Serving as both Principal Investigator and Ph.D. Supervisor, and having been Vice Director at a major clinical research center, Dr. Wang shows strong leadership and a commitment to research training.

  6. Recognitions and Awards
    Prestigious honors such as the Shanghai Leading Overseas Talent, Shanghai Pujiang Talent, and MSK Society Scholar Award (twice) underline peer recognition and scientific excellence.

🛠️ Areas for Improvement:

  1. Clinical Translation and Implementation
    While his preclinical work is strong, more details or evidence on how these findings have progressed toward clinical trials or therapeutic products could further strengthen his translational profile.

  2. Interdisciplinary Collaborations
    Expanding collaborations across fields like bioengineering, immunotherapy, or computational biology may add further value and broaden research impact.

  3. Visibility and Outreach
    Increasing visibility through keynote lectures, patents, or public datasets could enhance his reputation globally and support broader dissemination of his work.

  4. Grants and Funding Portfolio
    While not detailed in the CV, highlighting national/international grant leadership or participation would provide insight into his ability to secure and manage competitive research funding.

🎓 Education:

Dr. Yuxiang Wang holds a distinguished academic background across leading institutions. He completed his Ph.D. in Developmental and Molecular Biology at Albert Einstein College of Medicine (2008–2014), under Dr. Jeffrey W. Pollard, focusing on hormone signaling and uterine biology. Before that, he earned a Master of Sciences from Fudan University (2004–2007), mentored by Dr. Bo Chen, where he explored hormone interactions in reproductive biology. He began his academic journey with a Bachelor of Sciences from the Ocean University of China (2000–2004), majoring in life sciences. This robust education laid the foundation for his later success in cancer biology and translational research. Throughout his academic path, Dr. Wang has demonstrated a consistent focus on the cellular and molecular mechanisms underlying human diseases, especially cancer and genetic disorders. His education, blending rigorous laboratory work and clinical relevance, has uniquely positioned him for cutting-edge biomedical research.

💼 Experience:

Dr. Wang currently serves as Principal Investigator and Ph.D. Supervisor at Fudan University’s School of Basic Medical Sciences (2020–present), where he leads research on gliomas and muscular dystrophy. From 2021 to 2023, he also held the position of Vice Director of the Research Department at the Clinical Research Center of the Affiliated Children’s Hospital of Fudan University, coordinating clinical and translational projects. Prior to his return to China, Dr. Wang worked as a Research Fellow at Memorial Sloan-Kettering Cancer Center (2015–2020), collaborating with Dr. Timothy Chan and Dr. Jason Huse on the molecular basis of brain tumors and treatment resistance. His career bridges fundamental science and clinical applications, with a focus on leveraging genetic models and CRISPR technologies to uncover therapeutic targets. Dr. Wang’s international experience and leadership in high-impact research programs underscore his contributions to biomedical innovation and mentorship.

🏅 Awards and Honors:

Dr. Yuxiang Wang’s outstanding scientific contributions have been recognized through several prestigious awards. He was named a Shanghai Leading Overseas Talent (2020) and a Shanghai Pujiang Talent (2020), highlighting his excellence in international scientific exchange and leadership. While at Memorial Sloan-Kettering Cancer Center, he was twice awarded the MSK Society Scholar Award (2018, 2019), which recognizes exceptional postdoctoral researchers demonstrating strong potential for independent academic careers. These accolades underscore Dr. Wang’s commitment to impactful research, innovation in therapeutic development, and mentorship of young scientists. His ability to translate fundamental research into preclinical and potentially clinical solutions sets him apart as a research leader. These honors reflect peer recognition of both the depth and translational potential of his work in oncology and genetic diseases.

🔬 Research Focus:

Dr. Wang’s research centers on two critical areas: malignant gliomas and muscular dystrophy. In glioma studies, his team investigates the cooperative role of IDH and ATRX mutations using CRISPR-based genetic screening in mouse models to identify synthetic lethal targets—genes whose inhibition can selectively kill tumor cells with specific mutations. This strategy opens doors to novel, mutation-specific therapies with minimal harm to healthy cells. In muscular dystrophy, Dr. Wang focuses on rare genetic mutations affecting glycosylation pathways, utilizing patient-derived cells and animal models to evaluate gene therapy and genome editing solutions. His work seeks not only to understand disease mechanisms but also to bridge the lab-to-clinic gap. A long-term objective is to offer personalized therapies for patients with genetically defined diseases. The integration of molecular biology, translational research, and therapeutic innovation defines his approach.

📚 Publication Top Notes: 

  1. 🧬 Genetically Engineered Mouse Models Unveil Mechanisms and Therapeutic Strategies for GMPPB-Associated Dystroglycanopathy – Nature Communications (under revision)

  2. 🧠 PRICKLE4 Underlies IDH mutant Tumor Resistance against PARP Inhibition – Advanced Science (under revision)

  3. 🧫 Comprehensively characterizing eRNA in immune cells to screen combinational strategies for anti-cancer immunotherapy – Cancer Research (2025)

  4. 🔬 Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas – Science Advances

  5. 🧬 G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma – Nature Communications

  6. 🧪 Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence – Nature Genetics

  7. 🧠 Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling – Nature Communications

  8. 🧬 Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC–ERK1/2–mTOR signaling pathway – PNAS

  9. 🔬 GSK-3β mediates in the progesterone inhibition of estrogen-induced cyclin D2 nuclear localization and cell proliferation in cyclin D1−/− mouse uterine epithelium – FEBS Letters

🧾 Conclusion:

Dr. Yuxiang Wang is a highly deserving candidate for the Best Researcher Award. He demonstrates:

  • A clear and sustained record of scientific excellence,

  • Deep expertise in cancer biology and rare disease genetics,

  • Use of innovative methodologies, and

  • Leadership in both academic and clinical research environments.

His contributions to understanding the molecular basis of gliomas and developing targeted therapies for muscular dystrophy have significant implications for personalized medicine. With continued development in clinical translation and interdisciplinary reach, he stands out as a leader of the next generation of biomedical scientists.

Chen Huang | Cellular Bioenergetics Metabolism | Best Researcher Award

Published on by Cell Biologist

Dr. Chen Huang | Cellular Bioenergetics Metabolism | Best Researcher Award

Dr. Chen Huang , Shenzhen Institute of Advanced Technology (SIAT) Chinese Academy of Sciences (CAS) , China

Dr. Chen Huang is an Associate Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. She earned her Ph.D. in 2018 from the University of the Chinese Academy of Sciences. Her primary research lies at the intersection of female reproductive endocrinology and metabolic diseases, focusing on how adverse intrauterine environments impact long-term offspring health. Dr. Huang has authored over 20 SCI-indexed papers and holds 18 published patents with one under review. She has played significant roles in national and regional projects funded by the NSFC and Shenzhen Innovation Commission. Her notable contributions include identifying novel peptides with therapeutic potential in NAFLD and TNBC, and exploring molecular mechanisms behind pregnancy complications. Her impactful work, especially on metabolitin (MTL) and chemerin/GPR1 signaling pathways, has earned recognition in high-impact journals like Journal of Hepatology. Dr. Huang’s commitment to translational research places her at the forefront of biomedical innovation in women’s health.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Chen Huang exemplifies academic and scientific excellence through her impactful research in the fields of female reproductive endocrinology and metabolic diseases. Her contributions have led to meaningful advancements in understanding the molecular mechanisms that govern maternal-fetal health and associated disorders such as NAFLD, pregnancy complications, and cancer.

Key strengths include:

  • Scientific Innovation: She has identified and characterized novel peptide hormones such as metabolitin (MTL) and explored their therapeutic roles, a groundbreaking approach in targeting metabolic and oncological diseases.

  • High-Quality Publications: With around 20 SCI-indexed journal articles, including those in high-impact journals like Journal of Hepatology and Molecular Therapy – Oncolytics, her work is widely recognized in the scientific community.

  • Patent Portfolio: Dr. Huang has published 18 patents, with another under review, demonstrating her strong translational focus and commitment to real-world biomedical applications.

  • Research Leadership: She has successfully led multiple competitive national and regional research projects funded by the NSFC and Shenzhen Innovation Commission.

Areas for Improvement:

While Dr. Huang’s research output and contributions are impressive, certain enhancements could further elevate her global profile:

  • International Exposure: Engaging in more international collaborative projects or joint publications with global institutes could broaden the impact of her research.

  • Editorial and Professional Roles: Participation in editorial boards, peer review panels, or scientific committees would enhance her leadership presence in the scientific ecosystem.

  • Industry Engagement: Establishing collaborations with biotech or pharmaceutical industries could increase the translational value of her work and open pathways for clinical applications.

🎓 Education:

Dr. Chen Huang received her Ph.D. in 2018 from the University of the Chinese Academy of Sciences. Her doctoral research laid the foundation for her interest in female reproductive endocrinology and metabolic disorders, combining clinical insight with molecular research. Throughout her academic training, she focused on identifying the mechanistic links between endocrine disruptions during pregnancy and their long-term effects on offspring health. She has continually built upon this expertise through advanced training and interdisciplinary collaborations. Her educational background provided her with a robust understanding of molecular biology, endocrine physiology, and metabolic pathways, which she has applied in various research contexts—from liver disease to cancer biology. Her academic excellence was further highlighted by her early co-first authorship in high-impact journals during her Ph.D., demonstrating her ability to lead and innovate in collaborative research projects even in early stages of her career.

🧪 Experience:

Dr. Chen Huang is currently serving as an Associate Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. Since completing her Ph.D. in 2018, she has led and contributed to several key research projects, including those funded by the National Natural Science Foundation of China and the Shenzhen Science and Technology Innovation Commission. Her experience spans both basic and translational science, with an emphasis on hormonal regulation and metabolic diseases during pregnancy. She has collaborated with renowned scientists like Dr. Teng and Dr. Enkui Duan, contributing to the discovery of new peptide hormones such as metabolitin (MTL). Her professional experience is enriched by her ability to translate complex molecular findings into therapeutic strategies, especially in contexts like NAFLD and triple-negative breast cancer. With over 20 peer-reviewed SCI publications, her work reflects a consistent commitment to advancing biomedical research with clinical relevance.

🔬 Research Focus:

Dr. Chen Huang’s research focuses on the molecular underpinnings of female reproductive endocrinology and metabolic diseases, particularly within the context of pregnancy. She investigates how adverse intrauterine environments affect fetal development and contribute to long-term health issues in offspring. Her work explores key hormone-receptor interactions, such as the role of novel peptides (e.g., metabolitin) in liver disease and cancer. A major thread of her research also addresses the function of adipokines and their signaling pathways in pregnancy complications such as miscarriage and preeclampsia. Using both in vivo and in vitro models, she studies the regulatory mechanisms of trophoblast invasion, spiral artery remodeling, and immune cell interactions in the placenta. Her work integrates endocrinology, immunology, and developmental biology to identify new therapeutic targets. With an h-index of 12, she is recognized for her impactful publications and innovation in peptide-based treatments.

📚 Publications Top Notes:

  1. 🧬 Metabolitin (MTL) as a GPRC6A ligand improves NAFLD – Journal of Hepatology, 2020 (Co-first author)

  2. 🧪 Peptide blocks chemerin/GPR1 signaling to inhibit TNBC growth – Molecular Therapy – Oncolytics, 2020 (First author)

  3. 🔍 Adipokine promotes placental trophoblast invasion and vascular remodeling – Am J Physiol-Endocrinol Metab, 2019 (Co-first author)

  4. 🔬 mTOR hypoactivity causes trophectoderm failure via lysosomal activation – Cell and Bioscience, 2023

Conclusion:

Dr. Chen Huang is a highly deserving candidate for the Best Researcher Award. Her research contributions stand out in both innovation and societal impact, especially in the crucial domains of reproductive health and metabolic diseases. With a consistent publication record, numerous patents, and demonstrated research leadership, she is poised to make even greater scientific contributions in the years ahead. Recognizing her with this a